German drug giant Boehringer Ingelheim GmbH has signed a deal with U.S.-based biotech firm Vitae Pharmaceuticals to develop treatments for metabolic diseases. The deal enables Vitae to develop drugs that inhibit 11beta-HSD1, an enzyme that produces the hormone cortisol, which plays a role in such diseases as diabetes, obesity, hypertension and dyslipidemia, the companies said.

Full Story:

Related Summaries